Deal terms and valuation
H.B. Fuller, the U.S. adhesives manufacturer, has agreed to purchase Advanced Medical Solutions Group for a cash consideration that values the Winsford-based medical supplier at approximately A3715 million ($942.1 million) including debt. Shareholders of Advanced Medical Solutions will be paid 285 pence per share under the terms announced by the companies on Thursday.
Premium to recent market price
The 285 pence per-share offer represents a 35% premium to AMS's closing price on May 20 - the day before the start of the offer period. Following the announcement, AMS shares rose 15.8% to 278 pence, a level the stock has not seen since February 2023.
Timing and expected benefits
The parties said the transaction is expected to complete by the end of 2026. H.B. Fuller flagged anticipated cost and revenue advantages from combining the businesses, forecasting about $55 million in annual run-rate synergies by 2031. Management of both companies described the combination as creating a larger medical adhesives platform with expanded commercial, manufacturing and distribution capabilities.
Strategic context
Company commentary framed the acquisition as a means to accelerate strategy execution and broaden patient offerings across the U.S., Europe and other markets. Grahame Cook, Chair of AMS, said the combined platform would strengthen those capabilities and help deliver on the companies' strategy.
Process and shareholder support
The AMS board has unanimously recommended the cash transaction to shareholders. The deal follows an extended period of private equity interest in AMS, including activity in which TA Associates withdrew in May without making a bid; the companies' announcements also noted reported interest from Bridgepoint.
Market reaction and implications
AMS's share price reaction on the announcement reflected investor recognition of the premium and the potential upside from integration. The transaction is another example of an overseas buyer acquiring a London-listed company amid what the parties described as comparatively low UK valuations.